Two-Drug combo aims to stop lung cancer recurrence after surgery

NCT ID NCT06055465

Ongoing Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests whether combining sacituzumab govitecan (a targeted antibody-drug conjugate) with pembrolizumab (an immunotherapy) before and after surgery can improve outcomes for people with resectable non-small cell lung cancer (NSCLC). Participants receive four cycles of the drug combination before surgery, followed by 13 cycles of pembrolizumab alone after surgery. The study focuses on patients with stage II–III NSCLC that is EGFR/ALK-negative and aims to see how many achieve a complete pathological response (no cancer cells in the removed tissue).

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab govitecan and pembrolizumab
What this could lead to: If successful, this combination could lower the chance of lung cancer returning after surgery and improve survival for patients with resectable disease.
What could go wrong: This is an early phase 2 study with only 37 participants, so results may not apply to all patients. The drug combination may cause side effects like fatigue, nausea, or immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER

Contacts and locations

Locations

Department of Clinical Oncology, Prince of Wales Hospital

Hong Kong, Hong Kong
Department of Clinical Oncology, Queen Elizabeth Hospital

Hong Kong, Hong Kong
Department of Clinical Oncology, Tuen Mun Hospital

Hong Kong, Hong Kong
Department of Oncology, Princess Margaret Hospital

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.